March 28 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:
LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK FOR LX9851
LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR UP TO $75 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS
LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR $1 BILLION IN TOTAL PAYMENTS
LEXICON PHARMACEUTICALS INC - ENTITLED TO TIERED ROYALTIES ON NET SALES OF LX9851
LEXICON - NOVO NORDISK WILL BE RESPONSIBLE FOR FILING IND, ALL FURTHER DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF LX9851
Source text: ID:nGNX4hDsrs
Further company coverage: LXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.